These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 32833221

  • 61. Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?
    Grant D, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST.
    Liver Transpl; 2011 Oct; 17 Suppl 2():S133-8. PubMed ID: 21634006
    [No Abstract] [Full Text] [Related]

  • 62. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, De Carlis L, Belli L, Colledan M, Fagiuoli S, Rossi G, Andorno E, Baccarani U, Regalia E, Vivarelli M, Donataccio M, Cillo U, Liver Transplantation North Italy Transplant program (NITp) working group.
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [Abstract] [Full Text] [Related]

  • 63. [Selection criteria decisive in hepatocellular carcinoma].
    Söderdahl G, Eilard MS, Rizell M.
    Lakartidningen; 2014 Feb; 109(39-40):1750-3. PubMed ID: 23097883
    [No Abstract] [Full Text] [Related]

  • 64. Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation.
    Han S, Lee S, Yang JD, Leise MD, Ahn JH, Kim S, Jung K, Gwak MS, Kim GS, Ko JS.
    Liver Transpl; 2018 Jan; 24(1):44-55. PubMed ID: 29024412
    [Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66. Liver transplantation for hepatocellular carcinoma: a single European centre experience.
    Yedibela S, Förtsch T, Hohenberger W, Meyer T.
    Langenbecks Arch Surg; 2004 Apr; 389(2):104-9. PubMed ID: 14985986
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Taketomi A, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y, Ikegami T, Uchiyama H, Yoshizumi T, Soejima Y, Shirabe K, Maehara Y.
    Ann Surg Oncol; 2010 Sep; 17(9):2283-9. PubMed ID: 20204531
    [Abstract] [Full Text] [Related]

  • 73. Feasibility of using marginal liver grafts in living donor liver transplantation.
    Lan X, Zhang H, Li HY, Chen KF, Liu F, Wei YG, Li B.
    World J Gastroenterol; 2018 Jun 21; 24(23):2441-2456. PubMed ID: 29930466
    [Abstract] [Full Text] [Related]

  • 74. Feasibility and Safety of Split-Liver Transplantation in a Nascent Framework of Deceased Donation.
    Cherukuru R, Reddy MS, Shanmugam NP, Rajalingam R, Kota V, Gunasekaran V, Narasimhan G, Kaliamoorthy I, Rela M.
    Liver Transpl; 2019 Mar 21; 25(3):450-458. PubMed ID: 30586233
    [Abstract] [Full Text] [Related]

  • 75. Long-term Outcomes and Risk Factors After Adult Living Donor Liver Transplantation.
    Imai D, Yoshizumi T, Sakata K, Ikegami T, Itoh S, Harada N, Motomura T, Toshima T, Mano Y, Soejima Y, Maehara Y.
    Transplantation; 2018 Sep 21; 102(9):e382-e391. PubMed ID: 29912047
    [Abstract] [Full Text] [Related]

  • 76. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.
    Gordon FD, Goldberg DS, Goodrich NP, Lok AS, Verna EC, Selzner N, Stravitz RT, Merion RM.
    Liver Transpl; 2016 Sep 21; 22(9):1214-22. PubMed ID: 27339253
    [Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Liver Transplantation for Hepatic Epithelioid Hemangioendothelioma Is Facilitated by Exception Points With Acceptable Long-term Outcomes.
    Brahmbhatt M, Prenner S, Bittermann T.
    Transplantation; 2020 Jun 21; 104(6):1187-1192. PubMed ID: 31577674
    [Abstract] [Full Text] [Related]

  • 79. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation.
    Lee KW, Suh SW, Choi Y, Jeong J, Yi NJ, Kim H, Yoon KC, Hong SK, Kim HS, Lee KB, Suh KS.
    Liver Transpl; 2017 Jan 21; 23(1):19-27. PubMed ID: 27540701
    [Abstract] [Full Text] [Related]

  • 80. Surgical treatment of hepatocellular carcinoma.
    Sugawara Y, Hibi T.
    Biosci Trends; 2021 Jul 06; 15(3):138-141. PubMed ID: 33746184
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.